Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its earnings results on Tuesday. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01), Morningstar.com reports.
Shares of NASDAQ CYCC opened at $0.45 on Wednesday. The firm has a market cap of $9.29 million, a P/E ratio of -0.72 and a beta of 2.98. Cyclacel Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $1.87. The company has a quick ratio of 8.09, a current ratio of 8.09 and a debt-to-equity ratio of 0.08. The stock has a 50 day moving average price of $0.56.
Several equities research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. HC Wainwright reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Wednesday, May 15th. Finally, Roth Capital reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Thursday, May 23rd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $5.00.
A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC raised its position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,102,400 shares of the biotechnology company’s stock after purchasing an additional 498,200 shares during the period. Renaissance Technologies LLC owned 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.36% of the company’s stock.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Further Reading: Google Finance Portfolio Workaround
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.